O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003613
Recruitment Status : Terminated
First Posted : January 27, 2003
Last Update Posted : January 11, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells

Condition or disease Intervention/treatment Phase
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Drug: O6-benzylguanine Drug: carmustine Other: laboratory biomarker analysis Phase 1

Detailed Description:


I. To determine the kinetics of AGT depletion in CTCL skin lesions. II. To determine the toxicity of low dose BCNU plus O6BG.

OUTLINE: This is a dose-escalation study of carmustine.

Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of carmustine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

Patients are followed for 6 weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma
Study Start Date : April 1999
Actual Primary Completion Date : May 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Carmustine

Arm Intervention/treatment
Experimental: Treatment (O6-benzylguanine, carmustine)
Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Drug: O6-benzylguanine
Given IV
Other Name: BG

Drug: carmustine
Given topically
Other Names:
  • BCNU
  • BiCNU
  • bis-chloronitrosourea

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Percent decrease of AGT in CTCL skin lesions, obtained from tissue samples [ Time Frame: Baseline to 6 weeks ]
    Point and interval estimates of response using the binomial distribution will be obtained using data from patients with measurable or evaluable disease. If responses occur, then the mean and median duration of response will be determined. Statistical significance will be determined using the t test for analysis of continuous data.

  2. MTD of carmustine estimated as the dose level which is one level below where >= 2 DLT are observed [ Time Frame: 6 weeks ]
    Toxicities will be recorded and tabulated. Additional point and interval estimates for the MTD will be obtained using the methods of logistic regression of the proportion of patients experiencing a dose-limiting toxicity of grade >= 2 and by conventional regression of the mean dose-limiting toxicities on dose level.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed CTCL, stages IA-IIA
  • Performance status ECOG grade 0, 1, or 2
  • Patients must have recovered from toxicity of prior treatment and have received no CTCL therapy other than emoliation for at least 4 weeks
  • Patients must have signed a consent form indicating the investigational nature of the treatment and its potential side effects
  • WBC > 4,000/ul
  • ANC > 2,000/ul
  • Platelets > 100,000/ul
  • Bilirubin < 1.5 mg/dL
  • SGOT within normal range
  • Prothrombin time within normal range
  • Creatinine =< 1.5 mg/dL or creatinine clearance >= 70 ml/min
  • Calcium and electrolytes normal
  • Glucose-controlled (diet and insulin) diabetes is permitted
  • DLCO > 80% normal with the exception of patients who demonstrate clinically normal lung function based on history, physical examination, and chest x-ray as interpreted by the principal investigator
  • Only those patients with biopsiable tumor and willing to undergo several biopsies will be eligible
  • Must have failed 1 conventional treatment other than topical corticosteroids; this includes UVB, PUVA, topical mechlorethamine, electron beam, photopheresis, chemotherapy and immuno-modulatory agents such as cytokines

Exclusion Criteria:

  • Patients with a prior treatment with a nitrosourea
  • Patients with known central nervous system involvement or primary CNS malignancies will be ineligible
  • Patients with performance status ECOG grade 3 or 4
  • Pregnant women, women who are breast feeding infants, or women with reproductive potential not practicing adequate contraception, because of potential toxicity to the fetus or infant
  • Patients with active infection
  • Patients with pulmonary disease as determined by history, physical examination, chest X-ray or pulse oximetry
  • CTCL patients with stage IIB-IVB disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00003613

United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Kevin Cooper Case Western Reserve University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00003613     History of Changes
Other Study ID Numbers: NCI-2012-03119
CWRU 6496
U01CA062502 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: January 11, 2013
Last Verified: January 2013

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors